Background illustration for clinical trials search

Paid Clinical Trials Portland

Discover 149 paid clinical trials in Portland, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

for
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR),
Location: Westbrook ME, Toronto, Indianapolis IN, Zion IL,
Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT07403721

Phase1, Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

for
Breast Neoplasms
Location: Westbrook ME, Burlington MA, New York NY,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07173751

Phase3, Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

for
Metastatic Gastric Adenocarcinoma,
Location: Westbrook ME, Florham Park NJ, Flemington NJ,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07043400

Phase3, Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for
Carcinoma, Non-Small-Cell Lung
Location: Westbrook ME, Worcester MA, Burlington VT, Hartford CT,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06890598

Phase3, Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for
Non Small Cell Lung Cancer
Location: Westbrook ME, Greenfield Park, Montreal, Stony Brook NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06312137

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

for
Non-small Cell Lung Cancer
Location: Westbrook ME, Farmington CT, Albany NY, Stamford CT,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07190248

Phase3, Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Location: Westbrook ME, Boston MA, Sherbrooke, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06966700

Phase3, Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

for
Non-small Cell Lung Cancer (NSCLC)
Location: Westbrook ME, Mississauga, Brampton, Rochester MN,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06170788

Phase3, Recruiting

The THOR IDE Study

for
Peripheral Artery Disease, Peripheral Artery Stenosis,
Location: Portland ME, Leominster MA, Providence RI,
Sponsor: Philips Clinical & Medical Affairs Global

Sex: All

Age: 18+

Code: NCT05916950

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Scarborough ME, Montreal, West Haven CT, Saint John,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06692738

Phase3, Recruiting

GLP-1R Actions on Muscle and the Skeleton

for
Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity,
Location: Scarborough ME
Sponsor: Pennington Biomedical Research Center

Sex: All

Age: 18 - 50

Code: NCT07154719

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for
Non-small Cell Lung Cancer (NSCLC)
Location: South Portland ME, Boston MA, East Syracuse NY, Moncton,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07291037

Phase3, Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Scarborough ME, Burlington MA, Lebanon NH,
Sponsor: Olema Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07085767

Phase3, Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

for
Endometrial Cancer, Malignant Solid Tumour
Location: Scarborough ME, Stony Brook NY, White Plains NY,
Sponsor: AstraZeneca

Sex: Female

Age: 18+

Code: NCT07044336

Phase3, Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

for
Cardiovascular Disease
Location: Scarborough ME, Boston MA, Lebanon NH, Brookline MA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07000357

Phase3, Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

for
Metastatic Head-and-neck Squamous-cell Carcinoma,
Location: South Portland ME, Boston MA, Montreal, New Haven CT,
Sponsor: AVEO Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06064877

Phase3, Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

for
Non-squamous Non-small Cell Lung Cancer
Location: South Portland ME, Montreal, West Haven CT,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06627647

Phase3, Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

for
Cardiovascular Disease and Lipoprotein(a)
Location: Scarborough ME, Boston MA, Lebanon NH, Hartford CT,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT07517263

Phase3, Recruiting

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

for
Atrial Fibrillation
Location: Scarborough ME, Burlington MA, Boston MA, Providence RI,
Sponsor: Johns Hopkins University

Sex: All

Age: 22 - 70+

Code: NCT05836987

Phase3, Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

for
Locally Advanced Solid Tumors, Metastatic Solid Tumors,
Location: Scarborough ME, Boston MA, Montreal, Ottawa,
Sponsor: Turning Point Therapeutics, Inc.

Sex: All

Age: 0 - 25

Code: NCT04094610

Phase1, Phase2, Recruiting